大黄蛰虫丸加减联合奥拉帕利治疗乳腺癌基因突变型卵巢癌

Modified Dahuang Zhechong Pill combined with Olaparib for the treatment of ovarian cancer with breast cancer gene mutations

目的研究大黄蛰虫丸加减联合奥拉帕利治疗乳腺癌基因(breast cancergene,BRCA)突变型卵巢癌的疗效及对癌胚抗原(car-cinoembryonic antigen,CEA)、糖类抗原125(carbohydrate antigen 125,CA125)、糖类抗原199(carbohydrate antigen 199,CA199)水平的影响。方法纳入2021年2月至2023年2月在河南中医药大学第三附属医院进行手术治疗的98例卵巢癌患者的临床资料,根据治疗方式将患者分为对照组(n=49)和观察组(n=49),对照组采用奥拉帕利进行干预,观察组采用大黄蛰虫丸加减联合奥拉帕利进行干预,观察两组治疗前后临床疗效、肿瘤标志物CEA、CA125、CA199水平和药物不良反应。结果治疗后观察组CEA、CA125、CA199水平低于对照组(P<0.05);观察组治疗期间的恶心、肝肾功能异常、疼痛发生率均低于对照组(P<0.05);治疗前两组中医症候(小腹胀痛、纳差、面色晦暗)评分差异无统计学意义(P>0.05);治疗后,两组小腹胀痛、纳差、面色晦暗评分均降低,且观察组评分低于对照组(P<0.05);观察组西医治疗有效率(83.67%)高于对照组(55.10%)(P<0.05);对照组中医治疗有效率(53.06%)低于观察组(83.67%)(P<0.05)。结论大黄蛰虫丸加减联合奥拉帕利治疗BRCA突变型乳腺癌能够起到提高临床疗效、减少药物不良反应的作用。

Objective To analyze the efficacy of modified Dahuang Zhechong pill combined with olaparib tablets in ovarian can-cer patients with BRCA mutations and its impact on carcinoembryonic antigen(CEA)、carbohydrate antigen 125(CA125)、carbohydrate antigen 199(CA199)levels.Methods Clinical data of 98 patients with ovarian cancer underwent surgical treatment in our hospital from February 2021 to February 2023 were retrospectively analyzed.Patients were redivided into two groups for different treatment regimes,each with 49 cases.Control group received olaparib tablets,while observation group received modified Dahuang Zhechong pill com-bined with olaparib tablets.Then the clinical efficacy,tumor markers(CEA,CA125,CA199)and adverse drug reactions were observed in both groups.Results Serum levels of CEA,CA125 and CA199 were notably lower in the observation group than in the control group(P<0.05).The incidence of nausea,liver and kidney dysfunction and pain in the observation group were lower than those in the con-trol group(P<0.05).Before treatment,there was no statistically significant difference in the scores of traditional Chinese medicine symptoms(abdominal bloating and pain,poor appetite,and dull complexion)between the two groups(P>0.05);after treatment,the scores for abdominal bloating and pain,poor appetite,and dull complexion decreased in both groups,and the scores in the observation group were lower than those in the control group(P<0.05).The effective rate of western medical treatment(83.67%)in the observa-tion group was higher than that in the control group(55.10%)(P<0.05).The effective rate of traditional Chinese medicine treatment in the control group(53.06%)was lower than that in the observation group(83.67%)(P<0.05).Conclusion The combination of Da-huang Zhechong pill with olaparib for the treatment of BRCA-mutated breast cancer could improve clinical efficacy and reduce adverse drug reactions.